ADAM17 and breast carcinoma: One possible mechanism was recently identified by Gijsen and colleagues [48], who reported that blockade of Akt can activate ADAM17 (ADAM metallopeptidase domain 17) in erbB2-overexpressing breast cancer cells, leading to release of heregulins, which can act in an autocrine manner to activate erbB3.